Glaxosmithkline Consumer Healthcare Ireland Ip Limited was set up on Friday the 5th of December 2014. Their current partial address is Waterford, and the company status is Dissolved with the company closing on Wednesday the 10th of March 2021. The company's current directors have been the director of 18 other Irish companies between them; 9 of which are now closed. Glaxosmithkline Consumer Healthcare Ireland Ip Limited has 1 shareholder. This Irish company shares its Eircode with at least 2 other companies.
| Company Name: | Glaxosmithkline Consumer Healthcare Ireland Ip Limited |
| Company Status: | DISSOLVED |
| Company Address: | Knockbrack, Dungarvan, Waterford, Ireland |
| Key Executive: | Mr Lynch |
| Company Size: | Log-In To View |
| Established: | 05/12/2014 (7 years in business). |
Mr Lynch is a Company Director of Glaxosmithkline Consumer Healthcare Ireland Ip Limited since 2019 and a listed Director of 13 other companies.
Generate a B2B Marketing List with ease and grow your business. Identify key decision makers and pre-qualified new prospects for your sales and business development teams.
Similar Companies - Create a marketing list of similar companies
The latest documents filed with the Companies Registration Office for Glaxosmithkline Consumer Healthcare Ireland Ip Limited (which can include the Account Details) are listed below.
| CRO Document | Effective Date | Received By CRO | View Now | |
|---|---|---|---|---|
| E4 LIQUIDATOR PERIODIC STATEMENT OF ACCOUNT | 16/09/2020 | 27/11/2020 | Join Up | |
| E4 LIQUIDATOR PERIODIC STATEMENT OF ACCOUNT | 11/09/2020 | 27/11/2020 | Join Up | |
| E3 LIQUIDATORS A/C OF HIS ACTS AND DEALINGS | 11/09/2020 | 27/11/2020 | Join Up | |
| E5 LIQUIDATORS FINAL STATEMENT OF ACCOUNT | 16/09/2020 | 27/11/2020 | Join Up | |
| E6 FINAL WINDING UP MEETING - MEMBERS VOL WINDIN | 16/09/2020 | 27/11/2020 | Join Up | |
| THIS COMPANY HAS 46 OTHER DOCS » | ||||
View CRO company documents and company reports any Irish company or business with ease.
View the Latest Credit Report and Credit Limit on Glaxosmithkline Consumer Healthcare Ireland Ip Limited.
| Company Status: | Dissolved |
| Latest Credit Movement: |  |
| Date of Last Movement: | 27/11/2023 |
| Latest Accounts Filed: | 23/10/2018 |
| Report Based on Accounts: | 31/12/2017 |
| Next Set of Accounts Due: | 30/09/2019 |
| Overdue: | Yes |
| Credit Score: | Join-Up to View |
To View the latest Credit Rating or Credit Limit on Glaxosmithkline Consumer Healthcare Ireland Ip Limited simply click 'Log-In' or 'Join-Up' below.
Vision-net Credit Scores save your business the time and cost of chasing slow payers. Evaluate risk at client application stage or run continuous credit checks on your full customer base.
Satisfy due diligence requirements on Glaxosmithkline Consumer Healthcare Ireland Ip Limited in one single 'time-saving' search. Run full background checks for Fitness and Probity on the directors of Glaxosmithkline Consumer Healthcare Ireland Ip Limited and Anti-Money Laundering checks (AML checks) on Glaxosmithkline Consumer Healthcare Ireland Ip Limited
| Company Type: | LTD - Private Company Limited By Shares |
| Number of Shareholders: | 1 |
Log-in now to run Due Diligence checks and Compliance checks on Glaxosmithkline Consumer Healthcare Ireland Ip Limited or click Join-up to get started.
Background check Companies, Sole Traders or Individuals and minimise your spend with more efficient Anti-Money Laundering checks and reports.
More people choose Vision-net over any other search service... ask us why?
13/05/2025
If you're still asking customers to verify documents by email, it's time to upgrade.
05/05/2025
At CRIFVision-net, we recognise the growing importance of ESG indicators in today's business landscape, whether it?s for reputational reasons or part of your sustainability strategy.
29/04/2025
In line with the latest Corporate Sustainability Reporting Directive (CSRD) requirements, CRIFVision-net now provides ESG scores on every Irish company.
21/04/2025
In today's unpredictable economy, making informed business decisions while reducing risk can be challenging.
